esb世博网

Recently, CTTQ, a subsidiary of Sino Biopharm, and XtalPi, a drug discovery and development company driven by intelligent and automated technologies, announced a strategic collaboration to jointly develop new small molecule drugs for the treatment of malignant tumors against difficult targets.

China's biopharmaceutical industry is undergoing profound changes under the influence of both policy environment and market environment. Strengthening innovation at source and enhancing differentiation have become important tools for domestic pharmaceutical companies to improve their competitiveness and secure space for future development. The collaboration between XtalPi and CTTQ is a strong combination of an emerging biotech company with AI as its core and a large pharmaceutical group with research, production and sales. In this collaboration, XtalPi will use its AI and high-precision computational chemistry and other technology platforms to complete compound generation, evaluation and optimization, focusing on the discovery and optimization of innovative small molecule anti-tumor drugs.

"Our mission is to improve the quality of life by providing safe, effective and accessible medicines for unmet clinical therapeutic needs through continuous innovation and outstanding work," said Mr. Tse, Eric S Y, Executive Director of Sino Biopharm and Chairman of the CTTQ Pharmaceutical Group. "We attach great importance to the use of AI and other cutting-edge technologies to enhance the efficiency of new drug discovery and development. XtalPi is a leading company in applying AI technology to drug discovery and development, and we believe that through the strong combination of both partners and complementary advantages, we can accelerate the discovery of new drugs for difficult anti-tumor targets and develop high-quality oncology therapeutics, so that the urgent therapeutic needs of oncology patients can be met as soon as possible".

Dr. Ma Jian, co-founder and CEO of XtalPi, said, "Anti-tumor drug research and development has a very high social value, but also a very high technical difficulty. After the release of the "Clinical Value Oriented Clinical R&D Guidelines for Antineoplastic Drugs" by the State Drug Administration, the market has put forward higher requirements for the R&D of domestic antineoplastic drugs. CTTQ has been at the forefront of antineoplastic drug development in the industry, and we are very pleased to enter into this collaboration with CTTQ. XtalPi will use the intelligent drug discovery platform, combined with the strong technical capability and project experience of CTTQ, to jointly develop anti-tumor drugs with higher clinical value, while accelerating the drug development process for the benefit of society."

——About Sino Biopharm——

Sino Biopharm Limited and its subsidiaries are a leading innovative research and R&D-driven pharmaceutical group in China, with businesses spanning the entire industry chain of pharmaceutical R&D platforms, intelligent manufacturing and strong distribution systems. The products include a wide range of biologics and chemicals, and are in a dominant position in a number of high-potential therapeutic areas, including oncology, liver disease, cardiovascular disease, orthopedics, digestive system, anti-infection and respiratory diseases.

The company was listed on the Hong Kong Stock Exchange in 2000 and selected as a constituent of the MSCI Global Standard Index China in 2013; a constituent of the Hang Seng Index in 2018; a constituent of the Hang Seng China Enterprises Index in 2019; and a constituent of the Hang Seng Biotechnology 50 Index in 2020 and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. For three consecutive years, Sino Biopharm has been ranked among the "Top 50 Global Pharmaceutical Companies" by Pharmaceutical Executive, an authoritative magazine in the United States, and among the "Top 50 Best Companies in Asia Pacific" by Forbes (Asia) for three consecutive years.

——About CTTQ——

CTTQ is a leading innovative pharmaceutical group in China that integrates R&D, manufacturing and sales, and is committed to providing patients with high-quality and accessible therapeutic products. The company is a well-known leader in liver disease drugs in China and focuses on six product clusters: liver disease, oncology, respiratory, infection, endocrine and cardiovascular, with a focus on people's needs. It is a national key high-tech enterprise and ranked 15th in China's Top 100 Pharmaceutical Industries in 2020. The Group is a subsidiary of Sino Biopharm Limited (listed on the Hong Kong Stock Exchange, 1177).

The company has always taken scientific and technological innovation as a supporting force for its sustainable development, and its investment in R&D of innovative drugs is among the top in the industry, with annual R&D investment accounting for 12-15% of sales revenue. The continuous accumulation of innovation has earned the company the title of the best industrial enterprise in China's pharmaceutical R&D product line in the Ministry of Industry and Information Center for many years in a row.

——About XtalPi——

XtalPi is a quantum physics-based, AI-powered pharmatech platform dedicated to improving the speed, scale, novelty and success rate of drug discovery and development. With operations in both China and the U.S., it deploys the latest research and computational breakthroughs from around the world for its partners and collaborators.

XtalPi's intelligent drug discovery platform integrates cloud-based supercomputing digital R&D tools with advanced experimental capabilities to form a R&D system where high-precision predictions and targeted experiments corroborate and guide each other. As one of the world's pioneering AI drug discovery companies, XtalPi has established a set of R&D iterative processes that closely integrate quantum physics dry labs and advanced wet labs, challenging the efficiency bottleneck of traditional R&D and empowering new drug discovery to achieve breakthroughs in innovation speed and scale.